Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort
- PMID: 27557557
- DOI: 10.1007/s00467-016-3469-3
Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort
Erratum in
-
Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.Pediatr Nephrol. 2017 Jan;32(1):193-194. doi: 10.1007/s00467-016-3506-2. Pediatr Nephrol. 2017. PMID: 27704253 No abstract available.
Abstract
Background: There is a need for early identification of children with immunoglobulin A nephropathy (IgAN) at risk of progression of kidney disease.
Methods: Data on 261 young patients [age <23 years; mean follow-up of 4.9 (range 2.5-8.1) years] enrolled in VALIGA, a study designed to validate the Oxford Classification of IgAN, were assessed. Renal biopsies were scored for the presence of mesangial hypercellularity (M1), endocapillary hypercellularity (E1), segmental glomerulosclerosis (S1), tubular atrophy/interstitial fibrosis (T1-2) (MEST score) and crescents (C1). Progression was assessed as end stage renal disease and/or a 50 % loss of estimated glomerular filtration rate (eGFR) (combined endpoint) as well as the rate of renal function decline (slope of eGFR). Cox regression and tree classification binary models were used and compared.
Results: In this cohort of 261 subjects aged <23 years, Cox analysis validated the MEST M, S and T scores for predicting survival to the combined endpoint but failed to prove that these scores had predictive value in the sub-group of 174 children aged <18 years. The regression tree classification indicated that patients with M1 were at risk of developing higher time-averaged proteinuria (p < 0.0001) and the combined endpoint (p < 0.001). An initial proteinuria of ≥0.4 g/day/1.73 m2 and an eGFR of <90 ml/min/1.73 m2 were determined to be risk factors in subjects with M0. Children aged <16 years with M0 and well-preserved eGFR (>90 ml/min/1.73 m2) at presentation had a significantly high probability of proteinuria remission during follow-up and a higher remission rate following treatment with corticosteroid and/or immunosuppressive therapy.
Conclusion: This new statistical approach has identified clinical and histological risk factors associated with outcome in children and young adults with IgAN.
Keywords: IgA nephropathy; Pathology classification; Progression; Proteinuria; Risk factors.
Similar articles
-
Pediatric IgA Nephropathy in Europe.Kidney Dis (Basel). 2019 Jun;5(3):182-188. doi: 10.1159/000495751. Epub 2019 Jan 24. Kidney Dis (Basel). 2019. PMID: 31259180 Free PMC article. Review.
-
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.Kidney Int. 2014 Oct;86(4):828-36. doi: 10.1038/ki.2014.63. Epub 2014 Apr 2. Kidney Int. 2014. PMID: 24694989 Free PMC article.
-
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.Nephrol Dial Transplant. 2020 Jun 1;35(6):1002-1009. doi: 10.1093/ndt/gfy302. Nephrol Dial Transplant. 2020. PMID: 30418652
-
IgA nephropathy clinicopathologic study following the Oxford classification: Progression peculiarities and gender-related differences.Medicina (Kaunas). 2016;52(6):340-348. doi: 10.1016/j.medici.2016.11.003. Epub 2016 Nov 22. Medicina (Kaunas). 2016. PMID: 27932191
-
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22. Kidney Int. 2017. PMID: 28341274 Review.
Cited by
-
Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.Kidney Int Rep. 2023 Sep 22;8(12):2515-2528. doi: 10.1016/j.ekir.2023.09.020. eCollection 2023 Dec. Kidney Int Rep. 2023. PMID: 38106572 Free PMC article. Review.
-
IgA Nephropathy: A European Perspective in the Corticosteroid Treatment.Kidney Dis (Basel). 2018 Jun;4(2):58-64. doi: 10.1159/000487265. Epub 2018 Mar 16. Kidney Dis (Basel). 2018. PMID: 29998120 Free PMC article. Review.
-
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.Kidney Int Rep. 2021 Nov 24;7(2):305-318. doi: 10.1016/j.ekir.2021.11.012. eCollection 2022 Feb. Kidney Int Rep. 2021. PMID: 35155869 Free PMC article.
-
Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features.Kidney Int Rep. 2018 Mar 29;3(4):916-925. doi: 10.1016/j.ekir.2018.03.013. eCollection 2018 Jul. Kidney Int Rep. 2018. PMID: 29988999 Free PMC article.
-
Combined Therapy with Azathioprine, Prednisone, and Enalapril in Children with IgAN and IgAVN.J Clin Med. 2024 Dec 2;13(23):7316. doi: 10.3390/jcm13237316. J Clin Med. 2024. PMID: 39685773 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous